Simultaneous Targeting Tumor Cells and Cancer-Associated Fibroblasts with a Paclitaxel-Hyaluronan Bioconjugate: In Vitro Evaluation in Non-Melanoma Skin Cancer

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Jun 2

PMID 34073987

Citations 4

Authors

Barbara Bellei

Silvia Caputo

Emilia Migliano

Gianluca Lopez

Valeria Marcaccini

Carlo Cota

Mauro Picardo

Affiliations

Soon will be listed here.

Abstract

Background: Cancer-associated fibroblasts (CAFs) facilitate many aspects of cancer development by providing a structural framework rich in bioactive compounds. There are emerging studies proposing a combination of conventional anti-cancer therapies directed against neoplastic cells to molecules targeting tumor microenvironments.

Methods: The study evaluated the pharmacological properties of the anti-tumor agent paclitaxel conjugated to hyaluronic acid (HA) regarding non-melanoma skin cancer (NMSC) and the surrounding fibroblasts. This molecule, named Oncofid-P20 (Onco-P20), preferentially targets cells expressing high levels of CD44, the natural ligand of HA.

Results: Consistent with paclitaxel's mechanism of action involving interference with the breakdown of microtubules during cell division, highly sensitive carcinoma cells rapidly underwent apoptotic cell death. Interestingly, less sensitive cells, such as dermal fibroblasts, resisted the Onco-P20 treatment and experienced a prolonged growth arrest characterized by morphological change and significant modification of the gene expression profile. Onco-P20-treated fibroblasts exhibited reduced growth factor production, downmodulation of the Wnt signaling pathway, and the acquisition of a marked pro-inflammatory profile. Independently of direct exposure to taxol, in the presence of Onco-P20-treated fibroblasts or in their conditioned medium, carcinoma cells had a reduced proliferation rate. Similar to NHF, fibroblasts isolated from skin cancer lesions or from adjacent tissue acquired anti-neoplastic activity under Onco-P20 treatment.

Conclusion: Collectively, our data demonstrate that Onco-P20, exerting both a direct and an NHF-mediated indirect effect on carcinoma cells, is a candidate for an innovative therapy alternative to surgery for the treatment of NMSC.

Citing Articles

Fibroblasts as Turned Agents in Cancer Progression.

Wieder R Cancers (Basel). 2023; 15(7).

PMID: 37046676 PMC: 10093070. DOI: 10.3390/cancers15072014.

Macrophage-Derived Extracellular Vesicles: A Promising Tool for Personalized Cancer Therapy.

Barone A, dAvanzo N, Cristiano M, Paolino D, Fresta M Biomedicines. 2022; 10(6).

PMID: 35740274 PMC: 9220135. DOI: 10.3390/biomedicines10061252.

Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance.

De P, Aske J, Sulaiman R, Dey N Cancers (Basel). 2022; 14(6).

PMID: 35326670 PMC: 8946545. DOI: 10.3390/cancers14061519.

Hyaluronic Acid Coating Reduces the Leakage of Melittin Encapsulated in Liposomes and Increases Targeted Delivery to Melanoma Cells.

Li Y, Ruan S, Wang Z, Feng N, Zhang Y Pharmaceutics. 2021; 13(8).

PMID: 34452196 PMC: 8398362. DOI: 10.3390/pharmaceutics13081235.

References

Nilforoushzadeh M, Zare M, Zarrintaj P, Alizadeh E, Taghiabadi E, Heidari-Kharaji M . Engineering the niche for hair regeneration - A critical review. Nanomedicine. 2018; 15(1):70-85. DOI: 10.1016/j.nano.2018.08.012. View

Jiang G, Xu W, Du J, Zhang K, Zhang Q, Wang X . The application of the fibroblast activation protein α-targeted immunotherapy strategy. Oncotarget. 2016; 7(22):33472-82. PMC: 5078111. DOI: 10.18632/oncotarget.8098. View

Villani A, Cinelli E, Fabbrocini G, Lallas A, Scalvenzi M . Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opin Drug Saf. 2020; 19(12):1585-1594. DOI: 10.1080/14740338.2020.1837773. View

Grugan K, Miller C, Yao Y, Michaylira C, Ohashi S, Klein-Szanto A . Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci U S A. 2010; 107(24):11026-31. PMC: 2890722. DOI: 10.1073/pnas.0914295107. View

Flaberg E, Markasz L, Petranyi G, Stuber G, Dicso F, Alchihabi N . High-throughput live-cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts. Int J Cancer. 2010; 128(12):2793-802. DOI: 10.1002/ijc.25612. View

Eisemann N, Waldmann A, Geller A, Weinstock M, Volkmer B, Greinert R . Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol. 2013; 134(1):43-50. DOI: 10.1038/jid.2013.304. View

Silzle T, Randolph G, Kreutz M, Kunz-Schughart L . The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer. 2003; 108(2):173-80. DOI: 10.1002/ijc.11542. View

Wong H, Riabowol K . Differential CDK-inhibitor gene expression in aging human diploid fibroblasts. Exp Gerontol. 1996; 31(1-2):311-25. DOI: 10.1016/0531-5565(95)00025-9. View

Bechtel W, McGoohan S, Zeisberg E, Muller G, Kalbacher H, Salant D . Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 2010; 16(5):544-50. PMC: 3106179. DOI: 10.1038/nm.2135. View

10.

Sobel K, Tham M, Stark H, Stammer H, Pratzel-Wunder S, Bickenbach J . Wnt-3a-activated human fibroblasts promote human keratinocyte proliferation and matrix destruction. Int J Cancer. 2014; 136(12):2786-98. DOI: 10.1002/ijc.29336. View

11.

Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E . In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer. 2019; 146(4):895-905. PMC: 6972582. DOI: 10.1002/ijc.32193. View

12.

Bassi P, Volpe A, DAgostino D, Palermo G, Renier D, Franchini S . Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol. 2010; 185(2):445-9. DOI: 10.1016/j.juro.2010.09.073. View

13.

Zhang D, Yang R, Wang S, Dong Z . Paclitaxel: new uses for an old drug. Drug Des Devel Ther. 2014; 8:279-84. PMC: 3934593. DOI: 10.2147/DDDT.S56801. View

14.

Ozdemir B, Pentcheva-Hoang T, Carstens J, Zheng X, Wu C, Simpson T . Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25(6):719-34. PMC: 4180632. DOI: 10.1016/j.ccr.2014.04.005. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Espinosa-Cotton M, Rodman Iii S, Ross K, Jensen I, Sangodeyi-Miller K, McLaren A . Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. J Immunother Cancer. 2019; 7(1):79. PMC: 6425573. DOI: 10.1186/s40425-019-0550-z. View

17.

Silzle T, Kreutz M, Dobler M, Brockhoff G, Knuechel R, Kunz-Schughart L . Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol. 2003; 33(5):1311-20. DOI: 10.1002/eji.200323057. View

18.

Geary L, Nash K, Adisetiyo H, Liang M, Liao C, Jeong J . CAF-secreted annexin A1 induces prostate cancer cells to gain stem cell-like features. Mol Cancer Res. 2014; 12(4):607-21. PMC: 3989391. DOI: 10.1158/1541-7786.MCR-13-0469. View

19.

Morath I, Hartmann T, Orian-Rousseau V . CD44: More than a mere stem cell marker. Int J Biochem Cell Biol. 2016; 81(Pt A):166-173. DOI: 10.1016/j.biocel.2016.09.009. View

20.

Ziani L, Chouaib S, Thiery J . Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts. Front Immunol. 2018; 9:414. PMC: 5837994. DOI: 10.3389/fimmu.2018.00414. View